Sterling Capital Management LLC Purchases 78,829 Shares of Boston Scientific Corporation $BSX

Key Points

• Sterling Capital Management increased its Boston Scientific position by 1,344.7% in the third quarter, buying 78,829 additional shares for a total holding of 84,691 shares valued at $3.7 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific’s latest quarterly results exceeded expectations, with EPS of $0.86 versus the $0.83 consensus and revenue of $5.44 billion, up 7.5% year over year. The company provided fiscal 2026 EPS guidance of $3.28 to $3.32.
• Shares opened at $45.67, while analysts maintained a consensus “Moderate Buy” rating and a $68.23 price target despite several recent target reductions. Company directors and other insiders also purchased $9.4 million of stock over the past 90 days.

Sterling Capital Management LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 1,344.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,691 shares of the medical equipment provider's stock after purchasing an additional 78,829 shares during the period. Sterling Capital Management LLC's holdings in Boston Scientific were worth $3,697,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the first quarter worth about $28,000. Cassaday & Co Wealth Management LLC bought a new position in Boston Scientific during the first quarter valued at approximately $32,000. Measured Wealth Private Client Group LLC grew its holdings in Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 387 shares in the last quarter. Kelleher Financial Advisors purchased a new position in Boston Scientific during the 2nd quarter valued at approximately $25,000. Finally, Nvwm LLC grew its holdings in Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 542 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 0.7%

Shares of NYSE:BSX opened at $45.67 on Friday. The company has a market cap of $66.19 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.10 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $45.46 and a 200 day moving average price of $49.16.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Insider Activity

In related news, Director David Habiger bought 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on BSX. Barclays raised Boston Scientific to a "hold" rating in a research note on Wednesday, October 7th. Evercore lowered their target price on Boston Scientific from $65.00 to $52.00 and set an "outperform" rating for the company in a research report on Wednesday, October 7th. Sanford C. Bernstein reissued an "outperform" rating and issued a $54.00 target price (down from $60.00) on shares of Boston Scientific in a report on Saturday, October 3rd. Citigroup cut their target price on shares of Boston Scientific from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Monday, October 5th. Finally, Argus restated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $68.23.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.